Full-Time

Vice President

Global Corporate Communications

Posted on 3/26/2025

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical

1,001-5,000 employees

Develops therapies for rare genetic diseases

Compensation Overview

$313.2k - $386.9k/yr

+ Bonus + Equity Incentives

Expert

Cambridge, MA, USA + 4 more

More locations: Daly City, CA, USA | Bedford, MA, USA | Novato, CA, USA | Burlington, MA, USA

This role will typically require onsite work 2-3 days each week, or more depending on business needs.

Category
PR & Communications
Growth & Marketing
Required Skills
Communications
Social Media
Journalism
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Ultragenyx Pharmaceutical referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • 15 + years in the biotech/pharmaceutical industry, rare disease industry a plus
  • Bachelor’s degree in Communications, Journalism, or a related field.
  • Direct experience leading Corporate Communications at a public, global biotech company.
  • Excellent judgment, integrity, and transparency in leading and making decisions that are in the best interest of the Company.
  • Proven ability and experience in corporate communications and issues management on a global scale
  • Demonstrated ability to interact with all levels of the organization, as well as manage and lead projects involving cross-functional teams and excellent interpersonal skills.
  • Strong managerial, coaching and team-building skills.
  • Ability to plan, develop, and implement strategic internal and external communications programs using a variety of mediums.
  • Exceptional written, oral, and strategic communication skills, strong analytical skills and the ability to develop and implement strategic work plans and handle multiple projects simultaneously.
  • Ability to distill scientific/medical topics into clear and concise corporate messaging.
Responsibilities
  • Responsibility for all key global corporate communications functions, including concept development, writing/editing, production, and distribution; as well as management of the internal communications team and external agencies.
  • Develop materials for all general communications, reporting and special announcements, including key messages, fact sheets/backgrounders, presentations, conference call scripts, Q&As, press releases and briefing information. Ensures information complies with all product promotion guidelines, SEC regulations and adheres to relevant regulations.
  • Develop and implement a comprehensive global public relations strategy that aligns with business objectives and enhances our public image and narrative. Provide strategic oversight and integration of OUS activities.
  • Build and maintain strong relationships with key media outlets, journalists, and influencers. Lead proactive media outreach to secure press coverage and manage media inquiries.
  • Develop and manage digital and social media campaigns for the Company and enhance our digital communications strategy across all web, mobile and social channels to raise awareness of our corporate brand. Ensure consistent, on-brand messaging across all Company platforms.
  • Develop and execute a CEO and other XLT visibility strategy that includes securing top-tier events, op-eds, media interviews, speaking engagements, and thought leadership opportunities. Collaborate closely with additional senior executives to shape their messages and communications to raise the company's profile.
  • Collaborate across teams, including Commercial, Marketing, Medical Affairs, Patient Advocacy, Regulatory and Legal to develop and implement internal best practices to streamline, optimize and scale with growing external communications needs. Ensure activities across functions are all in-line with corporate goals / narrative.
  • Lead the development of proactive and reactive communication strategies for crisis and issues management. Work with internal teams to identify and address potential issues that could impact the company's reputation.
Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical

View

Ultragenyx Pharmaceutical develops therapies for rare and ultra-rare genetic diseases, focusing on conditions with limited treatment options. The company has a diverse pipeline of clinical-stage programs, allowing it to address multiple rare diseases simultaneously. Revenue is generated through the sale of FDA-approved therapies like burosumab and UX007, which validate their scientific approach. Ultragenyx aims to transform research into effective treatments while ensuring a consistent supply of medicines for patients.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Novato, California

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • GTX-102 in Phase III trials could lead Ultragenyx in Angelman syndrome treatment.
  • NICE's recommendation of Evkeeza boosts Ultragenyx's market presence in the UK.
  • Setrusumab development opens new therapeutic avenues for bone formation treatments.

What critics are saying

  • Intense competition in Angelman syndrome treatment may impact Ultragenyx's market share.
  • Setrusumab's success is uncertain, facing potential clinical and regulatory challenges.
  • Delays in NICE's recommendation for Evkeeza could affect Ultragenyx's revenue.

What makes Ultragenyx Pharmaceutical unique

  • Ultragenyx focuses on rare and ultra-rare genetic diseases with limited treatment options.
  • The company has a diversified product pipeline addressing multiple rare diseases simultaneously.
  • Ultragenyx's commitment to uninterrupted medicine supply ensures consistent patient treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Volunteer Days

Stock Options

Company Equity

Wellness Program

Professional Development Budget

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
BioSpace
Mar 17th, 2025
Opinion: Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx And Neuren

Several companies are working on new investigational treatments for Angelman syndrome, a rare genetic disorder that affects the nervous system and causes developmental delays, intellectual disability, seizures and speech impairment. Ionis and Ultragenyx are competing to bring investigational antisense oligonucleotide treatments to the market, while Neuren is betting on a synthetic peptide that can be delivered orally. It’s a tight race in a disease space with a high unmet need.Affecting 500,000 to 1 million patients worldwide, Angelman syndrome has no approved disease-modifying treatments. Although antiseizure medication is available, these drugs do not address the root cause, a genetic mutation in the UBE3A gene on chromosome 15. In Angelman syndrome, only the copy of the UBE3A gene inherited from the mother is functional, while the father’s allele is mutated.Both Ionis and Ultragenyx are currently in Phase III trials with their oligonucleotides, called ION582 and GTX-102, respectively. Meanwhile, Neuren is conducting a mid-stage trial on NNZ-2591, a twice-daily oral solution consisting of a synthetic peptide that modulates acetylcholine neurotransmission.Ionis’ ION582 is an investigational intrathecal injection that targets a long noncoding RNA to increase expression of the UBE3A protein in neurons

Arabic Week
Feb 20th, 2025
Global ANGPTL3-lowering therapy market is expected to reach US$ 785.21 million by 2031

Recent Developments In January 2024, Ultragenyx Pharmaceutical Inc. announced that the National Institute for Health and Care Excellence (NICE) has released a final draft guidance recommending Evkeeza (evinacumab) for use within NHS England.

GlobeNewswire
Jan 6th, 2025
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NOVATO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) - Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 10:30 AM PT.

Stat News
Jan 6th, 2025
The biotech scorecard for the first quarter: 16 stock-moving events to watch

Ultragenyx is developing an antibody treatment for the disease called setrusumab that works by blocking sclerostin, a protein that inhibits bone formation.

TipRanks
Nov 5th, 2024
Ultragenyx Reports Strong Q3 Growth and Milestones

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company dedicated to developing novel therapies for rare and ultra-rare genetic diseases, with a focus on advancing treatments where there are unmet medical needs.

INACTIVE